JP2017206538A - Abc transporter inhibitor - Google Patents

Abc transporter inhibitor Download PDF

Info

Publication number
JP2017206538A
JP2017206538A JP2017127860A JP2017127860A JP2017206538A JP 2017206538 A JP2017206538 A JP 2017206538A JP 2017127860 A JP2017127860 A JP 2017127860A JP 2017127860 A JP2017127860 A JP 2017127860A JP 2017206538 A JP2017206538 A JP 2017206538A
Authority
JP
Japan
Prior art keywords
nitroimidazole
dihydroxy
abc transporter
hydroxymethylpropyloxymethyl
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017127860A
Other languages
Japanese (ja)
Other versions
JP6306782B2 (en
Inventor
久保田 信雄
Nobuo Kubota
信雄 久保田
Original Assignee
株式会社ポーラファルマ
Pola Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社ポーラファルマ, Pola Pharma Inc filed Critical 株式会社ポーラファルマ
Priority to JP2017127860A priority Critical patent/JP6306782B2/en
Publication of JP2017206538A publication Critical patent/JP2017206538A/en
Application granted granted Critical
Publication of JP6306782B2 publication Critical patent/JP6306782B2/en
Application status is Active legal-status Critical
Anticipated expiration legal-status Critical

Links

Abstract

Provided is a means for treating cancer resistant to an anticancer drug. 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole represented by the following structural formula. An ABC transporter inhibitor used in the treatment of anticancer drug-resistant cancer under hypoxic conditions. [Selection figure] None

Description

  The present invention relates to an ABC transporter inhibitor that inhibits an ABC transporter involved in drug excretion in a hypoxic state. More specifically, the present invention relates to a cancer in which the effect of an anticancer drug or the like is reduced due to excessive drug excretion. ABC transporter inhibitors useful for the treatment of

  In cancer chemotherapy, the development of resistance to anticancer drugs has become an important issue that affects the therapeutic effect. The development of resistance to drugs is thought to be due to drug excretion by ABC transporters such as MDR. As means for inhibiting such drug excretion, quinoline derivatives have been developed and used for clinical trials, but development has been suspended (see Non-Patent Documents 1 and 2). In addition to these, transporter inhibitors include calcium antagonist verapamil, central drug desipramine, etc., all of which have higher main drug effects than inhibitory effects, and transporter inhibitors are Application was difficult.

  On the other hand, in cancer chemotherapy, there is a problem of hypoxic cells as well as the development of resistance by the transporter. Hypoxic cells have a high resistance to radiation, which is a major obstacle to cancer radiotherapy. As a means to solve this, a radiosensitizer using a 2-nitroimidazole derivative has been developed and is currently in clinical trials. (For example, refer to Patent Documents 1, 2, and 3). The hypoxic ABC transporter inhibitor of the present invention, 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole, is also radiosensitized to hypoxic cells. Has an effect. This is a compound that reduces the side effects due to the central orientation of misonidazole and exerts a hypoxic cell radiosensitization effect. In general, 2-nitroimidazole has a high orientation of the nervous system, and is therefore likely to develop neurotoxicity. It is known that misonidazole or RK-28 (1- (4-hydroxybutan-2-en-1-yl) -2-nitroimidazole) is also oriented in the brain across the brain-vascular barrier. This is said to be one of the causes of neurotoxicity. In addition, 2-nitroimidazole derivatives are easily oriented to hypoxic cells regardless of whether they are cancer cells or normal cells, and studies as markers for hypoxic cells are also being promoted (for example, Non-Patent Documents 3 and 4). , See Patent Document 4). Although having such a background, it was not known at all that such a compound inhibits the transporter in a hypoxic state regardless of the presence or absence of irradiation.

  The cerebral blood flow barrier is an organ that prevents harmful substances from flowing into the brain, and the reality is that chemical substances are discharged from the brain into the blood vessels by ABC transporters arranged on the blood vessels. It is known that there is. Because of the presence of these organs, the brain is not exposed to harmful substances. On the other hand, when treating brain diseases such as brain tumors, the cerebral blood flow barrier It interferes with arrival and makes treatment difficult. In other words, it can be said that development of a means for inhibiting the cerebral blood flow barrier when desired is desired. Furthermore, the development of such means is considered to be applicable to the treatment of cancer resistant to the above-mentioned anticancer agents, and it was also desired in this sense. Particularly, hypoxic cells having radiation resistance are strongly desired because the therapeutic effect can be remarkably improved if a drug can reach here. Furthermore, in brain tumors and the like, it is an important issue to prevent the drug from reaching parts other than the tumor.

Sato W, et. al. Cancer Res. 1991; 51 (9): 2420-4 Katayama R, et. al. Cancer Sci. 2009; 100 (11): 2060-8 Moenich D. et. al. Phys Med Biol. 2012; 57 (6): 1675-1684 Shibahara I. et. al. J Neurosurg. 2010; 113 (2): 358-68.

JP 2003-321459 A JP 2007-326814 A WO2008 / 090732 pamphlet WO01 / 019779 pamphlet

  The present invention has been made under such circumstances, and it is an object of the present invention to provide a means for improving the drug reachability only to the brain tumor part in a brain tumor and not improving the drug reach to the normal part of the brain. And

  In view of such a situation, the present inventors have made intensive research efforts to improve the drug reachability only to the brain tumor part and not to improve the drug arrival to the normal part of the brain in brain tumors. As a result of overlapping, 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole, which has the following structural formula, specifically inhibits the ABC transporter under hypoxic conditions. The present invention has been completed. That is, the present invention is as follows.

1- (2,3-Dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole

<1> above shows the structural formulas, and wherein the 1- (2,3-dihydroxy-1-hydroxymethyl-propoxymethyl) Ri Do -2-nitroimidazole, be used in the treatment of anticancer drug resistance cancers An ABC transporter inhibitor under hypoxic conditions.
<2> The ABC transporter inhibitor under hypoxic conditions according to <1>, which is used together with an anticancer agent.
<3> The ABC transporter inhibitor according to <1> or <2>, which is a drug discharge inhibitor under low oxygen conditions.
<4> above shows the structural formulas, and wherein the 1- (2,3-dihydroxy-1-hydroxymethyl-propoxymethyl) Ri Do -2-nitroimidazole, be used in the treatment of anticancer drug resistance cancers A drug effect enhancer under hypoxic conditions.
<5> The drug effect enhancer according to <4>, which is used together with an anticancer agent.

  ADVANTAGE OF THE INVENTION According to this invention, in a brain tumor, the chemical | medical agent reachability only to a brain tumor part can be improved, and the means which does not improve the arrival of a chemical | medical agent to the normal part of a brain can be provided.

  The ABC transporter inhibitor under hypoxic conditions of the present invention is characterized by comprising 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole having the above structure. . Such compounds have four isomers, any of which can be used. That is, 2 (R), 3 (R) -1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (hereinafter sometimes referred to as RR form), 2 (S) , 3 (S) -1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (hereinafter sometimes referred to as SS form), 2 (R), 3 (S)- 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (hereinafter sometimes referred to as RS form) and 2 (S), 3 (R) -1- (2,3 -Dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (hereinafter sometimes referred to as SR form). Moreover, the use with the racemic body which is these mixtures is also possible. Moreover, about the manufacturing method of these compounds, the details are described in Unexamined-Japanese-Patent No. 2003-321459, and it can manufacture according to this. That is, for example, the two hydroxyl groups of erythritol are protected with isopropylidene, the primary hydroxyl group is protected with a benzyl group, dimethoxymethane is reacted with phosphorus pentoxide as a catalyst, and the remaining hydroxyl group is converted to methoxymethyl ether. It is obtained by converting a group into an acetyl group with acetic anhydride and phosphorus pentoxide, condensing this with trimethylsilyl 2-nitroimidazole using a Lewis acid as a catalyst and then deprotecting.

2 (R), 3 (R) -1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole

2 (S), 3 (S) -1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole

2 (R), 3 (S) -1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole

2 (S), 3 (R) -1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole

  In the present invention, when 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole is used as an ABC transporter inhibitor under hypoxic conditions, the preferred dosage is , 10 mg / Kg to 5000 mg / Kg is preferable although it varies depending on the drug used for the subsequent treatment. This is because the administration of such dose of 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole inhibits the ABC transporter at the hypoxic site, thereby Control emissions. Since such a compound does not exhibit such an effect under oxygen conditions, neither the compound itself nor a drug such as an anticancer drug administered thereafter is inhibited from being discharged from the brain or the like in a normal brain. Therefore, it has an advantage of not expressing neurotoxicity. In addition, since only the transporter in the hypoxic state is inhibited, the subsequent drug arrives preferentially over the hypoxic cells with unfavorable treatment results. Can enhance the effect of drugs.

  When administering the ABC transporter inhibitor under the hypoxic condition of the present invention, the route of administration is selected from oral administration, intravenous administration, etc., injection or drip administration, rectal administration with suppositories, etc. In particular, in the case of administration to the brain or the like, administration by injection or infusion that acts accurately on the cerebral blood vessel barrier is preferable.

  The disease for which the ABC transporter inhibitor under the hypoxic condition of the present invention is used is a disease having a hypoxic region in the lesion, and it is necessary to deliver the drug to the hypoxic region in the lesion It is a certain disease. In such diseases, it is immediately preferable that the ABC transporter interferes with the drug orientation. Suitable examples of such diseases include brain tumors, ischemic heart diseases, cancers that are resistant to radiation and chemotherapeutic agents, such as lung adenocarcinoma, and the like.

  When the ABC transporter inhibitor under hypoxic conditions of the present invention is used, a drug for treating the disease after administration of this agent, an anticancer agent for cancer, and a myocardium for ischemic heart disease It is preferable to administer a protective agent or the like. Such a drug is oriented without being hindered by drug excretion at a site where drug excretion is inhibited by administration of the ABC transporter inhibitor under hypoxic conditions of the present invention. Thus, the effect of the drug can be enhanced.

  Hereinafter, the present invention will be described in more detail with reference to examples.

A cancer-bearing state was created by injecting 1 million C6 cells dispersed in 5 μL of FBS into the brains of 9-week-old WKAH / Hkm rats. While monitoring by MRI, it was confirmed that the size of the brain tumor was 50 mm 3 or more and used for the experiment. Rats, 1- (2,3-dihydroxy-1-hydroxymethyl-propoxymethyl)-2-14 C label in the nitroimidazole RS · SR racemic administered from 4.9MBq tail vein 90 minutes after administration The brain was removed and subjected to microautoradiography. At the same time, hematoxylin / eosin stained (HE stained) specimens were also prepared. Comparing autoradiography and HE-stained specimens, the presence of 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole is deep in brain tumors, and even deep inside brain tumors It turns out that it is dark. Since this deeply stained site does not overlap with the place showing the cell viability of HE staining, it is presumed that hypoxic cells are highly likely to exist. In other words, 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole appears to be oriented in the brain tumor from a site with high hypoxia. In the normal region, the presence of 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole is thin, and the characteristic of being difficult to orient in the original central nervous system has been reconfirmed. . Thus, 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole inhibits the ABC transporter constituting the cerebral blood flow barrier in hypoxia, and drug excretion Therefore, it was estimated that the concentration of 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole in the hypoxic region of the brain tumor was increased.

  1- (2,3-Dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (SR / RS racemate) is said to have high expression of MDR in oxygen and hypoxia conditions in the presence of 10 mM MTT assay was performed using PH69AR (MDR) SCLC cells and MES-SA / Dx5 (MDR). As a comparative example, the same study was performed for MES-SA (WT) cells with low MDR expression. The results are shown in Table 1. As a result, the effects of administration of 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (SR / RS racemate) are almost not affected in cells with low generation of ABC transporters such as MDR. Although there is no, it can be seen that cells with a high expression level of ABC transporters such as MDR have a reduced survival rate under hypoxic conditions. This is probably because ABC transporter is inhibited in the hypoxic region by 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (SR / RS racemate).

  Using RERF-LC-AI (human lum squamous carcinoma) under hypoxic conditions, anticancer agent and 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (SR / RS racemic) Body) was examined. The method used the MTT assay. The results are shown in Table 2. As a result, the presence of 1- (2,3-dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole (SR / RS racemate) inhibits the efflux transporter under hypoxic conditions. Was estimated.

Industrial application fields

  The present invention can be applied to medicine.

Claims (5)

  1. The structural formula shown below, Ri Do from 1- (2,3-dihydroxy-1-hydroxymethyl-propyloxy) -2-nitroimidazole, characterized in that it is used in the treatment of anticancer drugs resistant cancers, low ABC transporter inhibitor under oxygen conditions.
    1- (2,3-Dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole
  2.   The ABC transporter inhibitor under hypoxic conditions according to claim 1, wherein the ABC transporter inhibitor is used together with an anticancer agent.
  3. The ABC transporter inhibitor according to claim 1 or 2 , which is a drug excretion inhibitor under hypoxic conditions.
  4. The structural formula shown below, Ri Do from 1- (2,3-dihydroxy-1-hydroxymethyl-propyloxy) -2-nitroimidazole, characterized in that it is used in the treatment of anticancer drugs resistant cancers, low Drug effect enhancer under oxygen conditions.
    1- (2,3-Dihydroxy-1-hydroxymethylpropyloxymethyl) -2-nitroimidazole
  5. The drug effect enhancer according to claim 4 , which is used together with an anticancer agent.

JP2017127860A 2017-06-29 2017-06-29 ABC transporter inhibitor Active JP6306782B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017127860A JP6306782B2 (en) 2017-06-29 2017-06-29 ABC transporter inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017127860A JP6306782B2 (en) 2017-06-29 2017-06-29 ABC transporter inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013080745 Division 2013-03-22

Publications (2)

Publication Number Publication Date
JP2017206538A true JP2017206538A (en) 2017-11-24
JP6306782B2 JP6306782B2 (en) 2018-04-04

Family

ID=60414774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017127860A Active JP6306782B2 (en) 2017-06-29 2017-06-29 ABC transporter inhibitor

Country Status (1)

Country Link
JP (1) JP6306782B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018218094A1 (en) 2017-10-25 2019-04-25 Yazaki Corporation Electric distribution box

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929104A (en) * 1997-04-02 1999-07-27 Pola Chemical Industries, Inc. Method for inducing apoptosis of cancer cell
JP2007230958A (en) * 2006-03-03 2007-09-13 Pola Chem Ind Inc Enhancer of radiosensitization ability in hypoxic cell radiosensitizer
JP2007302609A (en) * 2006-05-12 2007-11-22 Pola Chem Ind Inc Agent for reinforcing radiation-sensitizing ability in hypoxic cell radiation sensitizer
CN101642452A (en) * 2008-08-06 2010-02-10 株式会社宝丽制药 Radiation sensitizer used for brain tumor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929104A (en) * 1997-04-02 1999-07-27 Pola Chemical Industries, Inc. Method for inducing apoptosis of cancer cell
JP2007230958A (en) * 2006-03-03 2007-09-13 Pola Chem Ind Inc Enhancer of radiosensitization ability in hypoxic cell radiosensitizer
JP2007302609A (en) * 2006-05-12 2007-11-22 Pola Chem Ind Inc Agent for reinforcing radiation-sensitizing ability in hypoxic cell radiation sensitizer
CN101642452A (en) * 2008-08-06 2010-02-10 株式会社宝丽制药 Radiation sensitizer used for brain tumor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BMC CANCER, vol. Vol. 13: 106, JPN6016040600, 8 March 2013 (2013-03-08) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018218094A1 (en) 2017-10-25 2019-04-25 Yazaki Corporation Electric distribution box

Also Published As

Publication number Publication date
JP6306782B2 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
AU2014207839C1 (en) Androgen receptor modulator and uses thereof
Maione et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
JP6147799B2 (en) Combination therapy with PARP inhibitors
DK2694072T3 (en) Combination of act-inhibitor relationship and abirateron for use in therapeutic treatments
JP5242877B2 (en) Administration of thiol-based chemical protectants
US9220680B2 (en) Compositions and methods for localized drug delivery through mammary papillae
Koukourakis Amifostine in clinical oncology: current use and future applications
JP5355856B2 (en) Compositions of VEGF antagonists and antiproliferative agents and their use for the treatment of cancer
US10111861B2 (en) Treatment of breast cancer
EP1358177B1 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
Kim et al. Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart
US10010542B2 (en) PFKFB3 inhibit and methods of use as an anti-cancer therapeutic
DE60030164T2 (en) 3-heteroarylidenyl-2-indolinone derivatives for modulating the activity of a protein kinase and for use in the chemotherapy of cancer
ES2204572T3 (en) Combined preparations including anthracicline derivatives and platinum derivatives.
Lee et al. Simvastatin inhibits NF-κB signaling in intestinal epithelial cells and ameliorates acute murine colitis
Perichon et al. An assessment of the in vivo effects of intravenous lipid emulsion on blood drug concentration and haemodynamics following oro-gastric amitriptyline overdose
US20160324829A1 (en) Combination therapy with parp inhibitors
EP2870161B1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
JP2012515184A (en) How to treat colorectal cancer
Shi et al. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity
Honkavaara et al. The effects of L-659,066, a peripheral α2-adrenoceptor antagonist, on dexmedetomidine-induced sedation and bradycardia in dogs
US5840742A (en) Pharmaceutical composition for inhibiting the growth of cancers
JP2007284446A (en) Benzimidazole-containing medicinal composition inhibiting cancer proliferation
US7468355B2 (en) Methods for inhibiting cancer and scar formation
RU2508116C2 (en) Methods and compositions for treating cancer

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180308

R150 Certificate of patent or registration of utility model

Ref document number: 6306782

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150